Table 1.
Patient Characteristics
| Total (n = 94) | SVR (n = 69) | Non-SVR (n = 25) | |
| Response to previous therapy (naive/relapser/NR) | 25/44/25 | 20/41/8 | 5/3/17 |
| Age | 57 (23–65) | 57 (23–65) | 56 (40–65) |
| Sex (M/F) | 52/42 | 42/27 | 10/15 |
| Height (cm) | 163.6 (141.8–189.2) | 164.7 (141.8–189.2) | 157.7 (148.5–181.5) |
| Weight (kg) | 61 (41–92.5) | 61.7 (41–92.5) | 58.8 (44.9–80.3) |
| rs8099917 (TT/TG/GG) | 50/41/3 | 47/21/1 | 3/20/2 |
| rs1127354 (CC/CA/AA) | 75/18/1 | 55/13/1 | 20/5/0 |
| Viral genotype (1b/others) | 93/1 | 69/0 | 24/1 |
| Core 70 (W/M/ND) | 50/43/1 | 43/26/0 | 7/17/1 |
| Core 91 (W/M/ND) | 48/45/1 | 39/30/0 | 9/15/1 |
| ISDR (0–1/≥2/ND) | 82/8/4 | 61/5/3 | 3/21/1 |
| WBC (/mm3) | 4800 (2800–8100) | 4900 (2800–8100) | 4660 (3000–7900) |
| Plt (×104/mm3) | 17.7 (9.1–33.8) | 18 (9.9–33.8) | 16 (9.1–23.9) |
| Hb (g/dL) | 14.3 (12.3–16.6) | 14.5 (12.5–16.5) | 14.1 (12.3–16.6) |
| ALT (IU/L) | 39 (12–302) | 38 (12–302) | 46 (17–135) |
| γGTP (IU/L) | 36 (11–233) | 33 (11–233) | 53 (19–226) |
| Virus titer (log IU/mL) | 6.7 (5.1–7.7) | 6.8 (5.1–7.7) | 6.7 (5.4–7.6) |
| Days to first ribavirin reduction | 17 (2–168) | 18 (2–168) | 14 (7–73) |
| Duration of telaprevir administration (days) | 85 (29–85) | 85 (29–85) | 84 (35–85) |
| Duration of peg-interferon injection (days) | 162 (22–165) | 162 (22–165) | 162 (30–165) |
| Duration of ribavirin administration (days) | 169 (29–169) | 169 (29–169) | 168 (36–169) |
| Effect of therapy (SVR/BT/TR/NR) | 69/4/19/2 | – | – |
NOTE. All patients were infected with genotype 1. Counts are listed for categorical values and the median and range are reported for continuous variables. ND, not determined, data unavailable.